BFC Planning’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.12M Buy
7,098
+1,067
+18% +$168K 0.04% 362
2026
Q2
$954K Buy
6,031
+1,705
+39% +$230K 0.04% 411
2026
Q1
$553K Buy
4,326
+2,668
+161% +$333K 0.02% 533
2025
Q4
$202K Buy
1,658
+680
+70% +$78K 0.01% 863
2025
Q3
$98K Sell
978
-101
-9% -$9.1K 0.01% 936
2025
Q2
$89.4K Sell
1,079
-1,836
-63% -$146K 0.01% 931
2025
Q1
$236K Sell
2,915
-287
-9% -$25.7K 0.02% 545
2024
Q4
$288K Sell
3,202
-267
-8% -$25.9K 0.02% 483
2024
Q3
$343K Buy
+3,469
New +$341K 0.03% 429

Other funds holding XBI

BFC Planning's XBI Position: Q3 2026 in Review

BFC Planning increased its State Street SPDR S&P Biotech ETF (XBI) stake by 18% in Q3 2026, buying an estimated $168K and bringing the position to 7,098 shares worth $1.12M. The position accounts for 0.04% of the portfolio, ranked #362.

BFC Planning first reported a position in XBI in Q3 2024 and has held it in 9 quarters since. 820 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • BFC Planning held 7,098 shares of State Street SPDR S&P Biotech ETF worth $1.12M as of Q3 2026.
  • BFC Planning bought 1,067 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $168K.
  • State Street SPDR S&P Biotech ETF made up 0.04% of BFC Planning's portfolio in Q3 2026, its #362 holding.
  • BFC Planning first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and has held it in 9 quarters since.
  • 820 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.